Independent and joint effects of body mass index and metabolic health in mid- and late-life on all-cause mortality: a cohort study from the Swedish Twin Registry with a mean follow-up of 13 Years

Peggy Ler1*, Xia Li2, Linda B. Hassing3, Chandra A. Reynolds4, Deborah Finkel1,5, Ida K. Karlsson1,2† and Anna K. Dahl Aslan1,2,6†

Abstract

Background: There is robust evidence that in midlife, higher body mass index (BMI) and metabolic syndrome (MetS), which often co-exist, are associated with increased mortality risk. However, late-life findings are inconclusive, and few studies have examined how metabolic health status (MHS) affects the BMI–mortality association in different age categories. We, therefore, aimed to investigate how mid- and late-life BMI and MHS interact to affect the risk of mortality.

Methods: This cohort study included 12,467 participants from the Swedish Twin Registry, with height, weight, and MHS measures from 1958—2008 and mortality data linked through 2020. We applied Cox proportional hazard regression with age as a timescale to examine how BMI categories (normal weight, overweight, obesity) and MHS (identification of MetS determined by presence/absence of hypertension, hyperglycemia, low HDL, hypertriglyceridemia), independently and in interaction, are associated with the risk of all-cause mortality. Models were adjusted for sex, education, smoking, and cardiovascular disease.

Results: The midlife group included 6,252 participants with a mean age of 59.6 years (range = 44.9—65.0) and 44.1% women. The late-life group included 6,215 participants with mean age 73.1 years (65.1—95.3) and 46.6% women. In independent effect models, metabolically unhealthy status in midlife increased mortality risks by 31% [hazard ratio 1.31; 95% confidence interval 1.12–1.53] and in late-life, by 18% (1.18;1.10–1.26) relative to metabolically healthy individuals. Midlife obesity increased the mortality risks by 30% (1.30;1.06–1.60) and late-life obesity by 15% (1.15; 1.04–1.27) relative to normal weight. In joint models, the BMI estimates were attenuated while those of MHS were less affected. Models including BMI-MHS categories revealed that, compared to metabolically healthy normal weight, the metabolically unhealthy obesity group had increased mortality risks by 53% (1.53;1.19—1.96) in midlife, and across all BMI categories in late-life (normal weight 1.12; 1.01–1.25, overweight 1.10;1.01–1.21, obesity 1.31;1.15—1.49). Mortality risk was decreased by 9% (0.91; 0.83–0.99) among those with metabolically healthy overweight in late-life.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: peggyler@outlook.com
†Ida K. Karlsson and Anna K. Dahl Aslan contributed equally to this work.
1 Aging Research Network-Jönköping (ARN-J), School of Health and Welfare, Jönköping University, Jönköping, Sweden
Full list of author information is available at the end of the article.
Background
From 1980 to 2015, the prevalence of obesity, commonly defined as a body mass index (BMI) of 30 kg/m² or greater, doubled among adults in more than 70 countries [1]. Excessive BMI is a putative risk factor for several major non-communicable diseases that are the principal causes of mortality. In 2015, an estimated four million deaths worldwide have been attributed to overweight, defined as BMI exceeding 25 kg/m², 61% of which were related to obesity [1]. Hence, the growing obesity epidemic raises critical public health concerns.

Several multi-country, population-based studies, with research participants of a wide age range between 20 and 80 years, have shown that high BMI increases mortality risk [2–5]. However, in age-stratified analyses, the BMI-mortality association among older persons weakened [3–6], in agreement with other studies of older individuals, which have reported a nonsignificant or even inverse association between high BMI in late-life and mortality [7–10]. Therefore, the effects of high BMI in late-life on mortality remain unclear.

High BMI often clusters together with other cardiometabolic factors, namely hypertension, dyslipidemia, and hyperglycemia, in what is known as metabolic syndrome (MetS) [11]. The prevalence of MetS is rising, resembling the obesity epidemic [12]. Although extensive research has demonstrated MetS as a risk factor for mortality, the evidence is primarily substantiated by studies of individuals less than 65 years [13, 14]. Some studies of older individuals, in contrast, have demonstrated a nonsignificant association between MetS and all-cause mortality [15, 16]. These findings suggest that the MetS-mortality association, like the BMI-mortality association, is likely moderated by age.

While high BMI often presents with MetS, they do not always co-exist. Obesity with the absence of MetS, signifying the preservation of metabolic health status (MHS), is referred to as metabolically healthy obesity (MHO) [17–20]. Interestingly, the MHO phenotype is not uncommon, and the prevalence of MHO in a population with obesity from 10 cohorts in Europe ranged from 35 to 76% in females and 22% to 57% in males [21]. Whether the MHO phenotype is a benign condition that confers lower mortality risk is, however, debatable. Some studies have demonstrated that MHO is associated with an elevated risk of mortality [22–24], but others have not [23, 25]. Furthermore, the mean ages of the study populations are generally less than 55 years, with follow-up ranging from about three to 30 years [24]. Research investigating the association between BMI-MHS phenotypes and mortality is scarce, especially in old age.

The increasing number of older individuals and the escalating prevalence of high BMI and MetS underscores the importance of elucidating how high BMI, MHS and their interactions predispose individuals to mortality. Therefore, we aimed to examine the independent and joint effects of BMI and MHS on the risk of all-cause mortality and investigate age-specific effects by studying the associations separately in measures taken in midlife and late-life.

Methods
Study population
The is a prospective, cohort study including participants from four sub-studies of aging in the Swedish Twin Registry, born from 1893 to 1958 [26]: GENDER [27], OCTO-Twin [28], SATSA [29] and TwinGene [30]. GENDER, OCTO-Twin and SATSA are longitudinal studies where various health status measures were collected in phases of self-reported questionnaires and in-person testing (IPT). The IPT included assessments of weight, height, blood pressure (BP) and venous blood sample collection. Licensed nurses performed the IPT at the participants’ homes or local healthcare centres. TwinGene is a cross-sectional study where participants underwent a health examination and venous blood sample collection. Licensed nurses performed the IPT at the participants’ homes or local healthcare centres. TwinGene is a cross-sectional study where participants underwent a health examination and venous blood sample collection at a local health care facility between 2004 and 2008. In this present study, the baseline was the first IPT with venous blood sample collection. Therefore, the baseline of this current study was between 1985 and 2008 (Fig. 1), which may occur at IPTs for different participants, depending on their age and wave of entry into the study, i.e., the study period spanned from baseline ranging from 1985 to 2008 to death or December 31st, 2020, whichever came first. All participants provided written informed consent, and the study was approved by Ethical Review Board in Stockholm (2015/1729 – 35/5).

Conclusions: MHS strongly influenced the BMI-mortality association, such that individuals who were metabolically healthy with overweight or obesity in mid- or late-life did not carry excess risks of mortality. Being metabolically unhealthy had a higher risk of mortality independent of their BMI.

Keywords: Metabolic syndrome, Body weight, Obesity, Metabolically healthy obesity, Metabolically benign obesity, Mortality
Assessing body mass index and metabolic health status

Height and weight were measured in light clothes (where participants were asked to remove their shoes, heavy items, or clothing) by trained nurses during the IPT. Systolic and diastolic BP was measured twice after 5 min of rest. Serum levels of glucose, haemoglobin A1C (HbA1c), triglycerides (TG) and high-density lipoproteins cholesterol (HDL-C) were analyzed from fasting (92.1%) and non-fasting (7.9%) blood samples. Diagnoses of diabetes, the use of diabetic medications and lipid-lowering medications were obtained from self-reported questionnaires or interviews during the IPT.

BMI was calculated by dividing weight in kilograms (kg) by the square of height in meters (m²) and categorized according to the WHO criteria [31] as follows: underweight (< 18.5), normal weight (18.5 – 24.9 kg/m²), overweight (25.0 – 29.9 kg/m²) and obese (≥ 30.0 kg/m²). Since few participants were underweight (n = 170, 1.3%), they were excluded from the analyses. Weight history was the maximum BMI recorded between ages 45 and 65, at a minimum of 5 years before the study baseline. The source of weight history may be IPT or self-reported from questionnaires. Weight history was categorized into normal weight, overweight or obese according to the WHO criteria mentioned above.

The National Cholesterol Education Program Adult Treatment Panel-III (NCEP ATP-III) criteria for Mets [32], previous literature [17, 21], and data availability guided the ascertainment of MHS in this study. Metabolically unhealthy (MU) status was defined as having at least two of the following NCEP ATP-III metabolic components: hypertension, hyperglycemia, hypertriglyceridemia, and decreased HDL. Table 1 shows the details of thresholds for each metabolic parameter. The presence of only one or none of the above indicated being metabolically healthy (MH).

Studying the interaction between BMI and MHS generated six different BMI-MHS phenotypes: metabolically healthy normal weight (MHN), metabolically unhealthy normal weight (MUN), metabolically healthy overweight (MHOw), metabolically unhealthy overweight (MUOw), metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO).
Covariates
Education (§7 years, 87 years, corresponding to basic versus more than a basic education for these birth cohorts) and smoking status (ever-smoker, never smoker) were self-reported during the studies. History of cardiovascular disease (CVD) was based on self-reports of angina pectoris, myocardial infarction, hypertension, angina, thrombosis of the legs, ischemic stroke or hemorrhagic stroke.

All-cause mortality
The STR is linked to several nationwide registers, including the Swedish Tax Agency, where information about participants’ vital status (the state of being alive or dead) and date of death was obtained. The outcome of interest was all-cause mortality, i.e., death due to any reason. Participants were followed from the age when BMI and MHS were measured at ages greater than 65 years (65.01 years), while the late-life group consisted of participants whose BMI and MHS were assessed until death or December 31st, 2020, depending on which came first.

Statistical analyses
We applied Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) of the individual and joint effects of BMI and MHS on the risk of all-cause mortality, with age as the underlying time scale. We selected age as a timescale in our analyses since age strongly correlates to the exposure of interest (BMI and MHS) and survival. Using age as a timescale allows us to account for the effects of age at study entry when exposures were measured, age at the end of the study, and age at death.

Participants were followed from the age of BMI and MHS assessment to death or end of follow-up (December 31st, 2020). We used stratified Cox models to account for differences among the sub-studies and robust standard errors to account for clustering within twin pairs. We divided the study population into two groups based on age at baseline in the analyses. The midlife group consisted of participants whose BMI and MHS were measured at ages 65 years or below (65.0 years), while the late-life group consisted of participants whose BMI and MHS were measured at ages greater than 65 years (65.01 years). The proportional hazards assumption was tested by comparing log–log survival plots and performing tests on Schoenfeld residuals for each independent variable in the main analysis. CVD in midlife and smoking in late-life variables did not satisfy the proportional hazard assumption and were thus specified as time-varying covariates.

Firstly, we examined the independent effects of BMI by estimating the association adjusted for the primary confounders, education, smoking and sex (Model 1), and further for CVD (Model 2). Then, the independent effects of MHS on the risk of mortality were investigated with the corresponding two models mentioned above (Model 3 and 4). Next, we estimated the joint effects of both BMI and MHS, adjusted for the primary confounders as above (Model 5), and further adjusted for CVD (Model 6).

Lastly, we included an interaction term between BMI and MHS, adjusted for primary confounders (Model 7) and further for CVD (Model 8), to study how BMI stratified by MHS was associated with mortality. We thereby estimated HRs with 95% CI for mortality of the six phenotypes generated from the cross-categorization of BMI and MHS: MUN, MHOw, MUow, MHO and MUO with MHN as the reference category. The normative groups (MHN, normal weight, and metabolically healthy category) were selected as the reference category in line with previous research.

Sensitivity analyses were performed based on models 7 and 8, using the full sample, first by adjusting for education, smoking and sex, then further adjusted for CVD. Since there is no consensus in the criteria for ascertaining metabolic health, we first investigated if the HRs and 95% CI were affected by applying five different ways of determining MHS: a) by including CVD history as an additional criterion in the definition; b) excluding self-reports, such as the use of diabetic medications, lipid-lowering medications and diabetes diagnosis; c) defining MH status as the absence of any metabolic abnormality; d) including waist circumference(WC) as an additional criterion in the definition. The thresholds for WC to indicate metabolic abnormality were 80 cm for females and 94 cm for males; e) we applied the new criteria established by Zembic et al. [33] and defined MH as the absence of the following: 1) systolic BP less than 130 mmHg, 2) waist-hip-ratio (WHR) less than 0.95 for women and less than 1.03 in men, 3) no prevalent diabetes. Secondly, we added weight history as a confounder to correct for potential bias from reverse causation. Next, we stratified the analyses by sex to detect sex differences in the BMI-MHS-mortality association. Lastly, we examined the individual effects of metabolic abnormalities used to define MHS by including them separately within the same model. All analyses were performed with STATA version 16.1.

Results
Baseline characteristics
After excluding participants with insufficient information to define any one of the four metabolic components (n = 598, 4.5%) or missing covariates (n = 87, 0.6%), we included 12,467 individuals in the analyses with a mean follow-up of 13 years (range 0.01 – 33.7). The mean follow-up time was derived from a study period that spanned from baseline ranging from 1985 to 2008 to
Table 2  Descriptive statistics of baseline characteristics of study participants by age at baseline, midlife and late-life

| Characteristics                          | Age categories |          |          |          |          |          |          |
|------------------------------------------|----------------|----------|----------|----------|----------|----------|----------|
|                                          | Midlife (< = 65 years) | Late-life (> 65 years) |          |          |          |          |
|                                          | Mean / n SD / % | Mean / n SD / % |          |          |          |          |
| Number of participants (n)               | 6252           | 6215     |          |          |          |          |
| Age at baseline, years (mean, SD)        | 59.6 4.18      | 73.1 5.93 |          |          |          |          |
| Sex, Males/Females (n, %)                | 2754/3498 44.05/55.95 | 2897/3318 46.61/53.39 |          |          |          |          |
| BMI, kg/m2 (mean, SD)                    | 26.06 3.94     | 26.01 3.81 |          |          |          |          |
| Systolic BP, mmHg (mean, SD)             | 134.99 18.33   | 147.30 20.84 |          |          |          |          |
| Diastolic BP, mmHg (mean, SD)            | 82.67 10.52    | 81.57 10.64 |          |          |          |          |
| Blood glucose, mmol/l (mean, SD)         |                |          |          |          |          |          |
| Non fasting (n = 387)                    | 4.88 1.33      | 5.30 2.13 |          |          |          |          |
| Fasting (n = 400)                        | 4.63 1.17      | 4.89 2.31 |          |          |          |          |
| HbA1c, % (mean, SD)                      | 4.75 0.65      | 4.90 0.69 |          |          |          |          |
| Type II Diabetes (n, %)                  | 300 4.82       | 555 8.98 |          |          |          |          |
| Diabetic medication use (n, %)            | 223 3.57       | 401 6.46 |          |          |          |          |
| Triglycerides, mmol/l (mean, SD)         |                |          |          |          |          |          |
| Non fasting (n = 506)                    | 1.63 1.20      | 1.78 0.97 |          |          |          |          |
| Fasting (n = 11,016)                     | 1.34 0.84      | 1.40 0.79 |          |          |          |          |
| HDL cholesterol, Males/Females, mmol/l (mean, SD) | 1.23/1.57 0.34/0.42 | 1.25/1.55 0.34/0.42 |          |          |          |          |
| Lipid-lowering medication use (n, %)     | 695 11.16      | 875 14.14 |          |          |          |          |
| Education, < = 7 years / > 7 years (n, %)| 1553/4699 24.84/75.16 | 2742/3473 44.12/55.88 |          |          |          |          |
| Ever smoker (n, %)                       | 3943 63.07     | 3172 51.04 |          |          |          |          |
| CVD (n, %)                               | 2021 32.33     | 2900 46.66 |          |          |          |          |
| BMI categories (n, %)                    |                |          |          |          |          |          |
| Normal weight                            | 2786 44.56     | 2677 43.07 |          |          |          |          |
| Overweight                               | 2581 41.28     | 2701 43.46 |          |          |          |          |
| Obesity                                  | 885 14.16      | 837 13.47 |          |          |          |          |
| Metabolically unhealthy (n, %)           | 2304 36.85     | 2831 45.55 |          |          |          |          |
| No. of Metabolic abnormalities (mean, SD) | 1.34 1.06      | 1.63 1.01 |          |          |          |          |
| Mortality (n, %)                         | 733 11.72      | 3419 55.01 |          |          |          |          |
| BMI * Metabolic Health Status (%)        |                |          |          |          |          |          |
| MHN                                       | 2178 34.84     | 1800 28.96 |          |          |          |          |
| MUN                                       | 608 9.72       | 877 14.11 |          |          |          |          |
| MHOw                                      | 1454 23.26     | 1282 20.63 |          |          |          |          |
| MUOw                                      | 1127 18.03     | 1419 22.83 |          |          |          |          |
| MHO                                       | 316 5.05       | 302 4.86 |          |          |          |          |
| MUO                                       | 569 9.10       | 535 8.61 |          |          |          |          |
| Weight History (%)                       |                |          |          |          |          |          |
| Normal weight                             | 3259 56.19     | 2617 58.14 |          |          |          |          |
| Overweight                                | 2107 36.33     | 1616 35.90 |          |          |          |          |
| Obesity                                   | 434 7.48       | 268 5.95 |          |          |          |          |

Baseline characteristics are presented as means and standard deviations (SD) for continuous variables; and frequencies (n) and percentages (%) for categorical variables. Individuals with measures taken in mid-and late-life are presented separately.

Abbreviations: BMI body mass index, BP blood pressure, CVD history of cardiovascular disease or cardiovascular surgeries, MHS metabolic health status, MHN metabolically healthy normal weight, MUN metabolically unhealthy normal weight, MHOw metabolically healthy overweight, MUOw metabolically unhealthy overweight, MHO metabolically healthy obesity, MUO metabolically healthy obesity. Normal weight was defined as having BMI 18.5 – 24.9 kg/m²; overweight 25 – 29 kg/m²; obesity ≥ 30 kg/m². Metabolically unhealthy status was defined as having ≥ 2 abnormal metabolic abnormalities. Metabolically healthy status was defined as having < 2 abnormal metabolic components.
death or December 31st, 2020, whichever came first. Table 2 summarizes the baseline characteristics of the study population. A total of 6,252 participants entered the study in midlife, and 6,215 participants entered in late-life. The mean baseline age and follow-up time were 59.6 (range 44.9 – 65.0) and 13.9 (1.0 – 33.7) years respectively in the midlife group and 73.1 (65.1 – 95.3) and 12.0 (0.01–30.8) years in the late-life group. The mean BMI was approximately 26 kg/m² at baseline in both the midlife and late-life sample, while the prevalence of MU status was higher in late-life. During follow-up, 733 deaths occurred in the midlife group at a mean age of 72.6 (60 – 96) years, and 3419 in the late-life group at a mean age of 85.2 (67 – 108) years.

**Independent and joint effects of BMI and MHS on the risk of mortality**

Table 3 shows how mid- and late-life BMI and MHS associate with mortality, independently and jointly, adjusted for the primary confounders, education, smoking, and sex, and further adjusted for CVD. Mid- and late-life obesity, but not overweight, were associated with 42% and 22% higher risk of mortality, respectively, compared to normal weight. Further adjustments for CVD attenuated the effects of midlife obesity to 30% and late-life obesity to 15%. Compared to the MH group, being MU in midlife was associated with a 43% rise in mortality risk and being MU in late-life was associated with 25% higher risk. Further adjustments for CVD slightly attenuated the effects of the MU group in mid- and late-life to 31% and 18%, respectively.

In the joint models, which include the effects of both BMI and MHS, we observed the most substantial differences in the HRs for obesity, which was attenuated to 25% when measured in midlife and 15% when measured in late-life. When further adjusted for CVD, the pattern of change in the independent effects and joint effects were identical. Notably, the association between midlife obesity and mortality became nonsignificant when CVD was added to the models. The HRs for MU in both midlife and late-life were generally similar in the independent effect and joint models. In the joint effect models, being MU in midlife was associated with an elevated mortality risk by 38% and in late-life by 25%. When further adjusted for CVD, midlife and late-life MU was associated with increased mortality risk by 28% and 18%, respectively.

**Interaction between BMI and MHS in relation to the risk of mortality**

Figure 2 presents the HRs and 95% CIs of BMI-MHS phenotypes, generated from the interaction between BMI and MHS, with MHN as the reference group for all-cause mortality. When adjusted for primary confounders, being MUOw or MUO in midlife heightened the risk of mortality by 31% and 73%, respectively. In contrast, being MHOw or MHO was not associated with a rise in mortality risk. After additional adjustment of CVD, the

| Table 3 | Multivariable Cox regression of all-cause mortality in relation to independent and joint effects of body mass index and metabolic health status |
| --- | --- |
| **Age Models** | Independent effects of BMI | Independent effects of MHS | Joint effects of BMI and MHS |
| **HR (95% CI)** | **HR (95% CI)** | **HR (95% CI)** | **HR (95% CI)** |
| **Adjustments** | Sex, Educ, Smoke | + CVD | Sex, Educ, Smoke | + CVD |
| **< = 65 years BMI categories** | 1.02 (0.87 – 1.21) | 0.99 (0.84 – 1.17) | 1.25 (1.003 – 1.55) | 1.38 (1.18 – 1.62) |
| Overweight | 1.42 (1.16 -1.75) | 1.30 (1.06 – 1.60) | 1.38 (1.18 – 1.62) | 1.28 (1.09 – 1.51) |
| Obesity | 1.43 (1.23 – 1.66) | 1.31 (1.12 – 1.53) | 1.38 (1.18 – 1.62) | 1.28 (1.09 – 1.51) |
| **MU status** | 0.96 (0.81 – 1.13) | 0.94 (0.80 – 1.12) | 0.96 (0.81 – 1.13) | 0.94 (0.80 – 1.12) |
| **> 65 years BMI categories** | 0.99 (0.93 – 1.07) | 0.96 (0.89 – 1.03) | 0.96 (0.89 – 1.03) | 0.94 (0.87 – 1.01) |
| Overweight | 1.22 (1.01 – 1.53) | 1.15 (1.04 – 1.27) | 1.25 (1.16 – 1.33) | 1.18 (1.10 – 1.26) |
| Obesity | 1.25 (1.17 – 1.34) | 1.18 (1.10 – 1.26) | 1.25 (1.16 – 1.33) | 1.18 (1.10 – 1.26) |

Hazard ratios with 95% confidence intervals from Cox regression models of all-cause mortality in relation to independent effects of body mass index (BMI), metabolic health status (MHS) and joint effects of BMI and MHS. Models 1, 3 and 5 were adjusted for sex, education attainment and smoking status. Models 2, 4 and 6 were adjusted for sex, education attainment, smoking status and history of cardiovascular disease. Bold numbers indicate significance at the α = 0.05 level

Abbreviations: HR hazard ratios, CI confidence interval, Educ education attainment, Smoke smoking status, + CVD additionally adjusted with history of cardiovascular disease, BMI body mass index, MU metabolically unhealthy
Fig. 2  Multivariable Cox Regression of all-cause mortality in relation to the interactions between body mass index and metabolic health status. Hazard ratios (HR) and 95% confidence intervals (CI) of all-cause mortality in relation to the interactions between body mass index (BMI) categories and metabolic health status, with metabolically healthy normal weight (MHN) as the reference group. We present Cox regression models adjusted for sex, education, and smoking, and with +CVD adjustment adjusted for sex, education, smoking and CVD. Bold numbers denote significance at the α ≤ 0.05 level. Abbreviations: CVD—history of cardiovascular disease, MUN – metabolically unhealthy normal, MHOw – metabolically healthy overweight, MUOw – metabolically unhealthy overweight, MHO – metabolically healthy obese and MUO – metabolically unhealthy obese. Normal weight is defined as having BMI 18.5 – 24.9 kg/m²; overweight 25 – 29.9 kg/m²; obesity ≥ 30.0 kg/m². MU is defined as having ≥ 2 abnormal metabolic abnormalities.

|            | Basic adjustment | +CVD adjustment | HR, 95% CI               |
|------------|------------------|-----------------|--------------------------|
| **Midlife, <=65 years** |                  |                 |                          |
| MUN        |                  |                 | 1.24, 0.94 - 1.64        |
|            |                  |                 | 1.15, 0.87 - 1.53        |
| MHOw       |                  |                 | 0.91, 0.74 - 1.13        |
|            |                  |                 | 0.90, 0.73 - 1.11        |
| MUOw       |                  |                 | 1.31, 1.06 - 1.61        |
|            |                  |                 | 1.20, 0.97 - 1.48        |
| MHO        |                  |                 | 1.12, 0.79 - 1.58        |
|            |                  |                 | 1.07, 0.76 - 1.50        |
| MUO        |                  |                 | 1.73, 1.36 - 2.20        |
|            |                  |                 | 1.53, 1.19 - 1.96        |
| **Late life, > 65 years** |                  |                 |                          |
| MUN        |                  |                 | 1.21, 1.09 - 1.34        |
|            |                  |                 | 1.12, 1.01 - 1.25        |
| MHOw       |                  |                 | 0.93, 0.85 - 1.02        |
|            |                  |                 | 0.91, 0.83 - 0.998       |
| MUOw       |                  |                 | 1.20, 1.09 - 1.31        |
|            |                  |                 | 1.10, 1.01 - 1.21        |
| MHO        |                  |                 | 1.14, 0.98 - 1.32        |
|            |                  |                 | 1.07, 0.92 - 1.23        |
| MUO        |                  |                 | 1.43, 1.25 - 1.63        |
|            |                  |                 | 1.31, 1.15 - 1.49        |

Hazard Ratios
HR for MUOw in midlife was attenuated and no longer significant; however, MUO was associated with a higher mortality risk at 53%.

In late-life, being MU increased mortality risk across all BMI categories compared to MHN (Fig. 2). Relative to MHN, the risk of mortality increased by 21% in MUN, 20% in MUOw, and 43% in MUO. When including CVD in the adjustment, HRs were slightly attenuated for all the MU phenotypes. Being MHOw in late-life was associated with a 9% lower risk of mortality. While individuals with MHO in late-life had higher HRs for mortality in all models, they were not statistically significant.

Sensitivity analyses
There were no striking sex differences in the findings, but the HRs were generally higher among males than females, particularly in midlife (Additional file 1, Tables S7a and S7b).

Overall, using other definitions of MHS affected the magnitude of effects but not the pattern or general conclusions (Additional file 1, Table S1 – S6). When we added CVD as an additional criterion in the assessment of MHS, the association between BMI-MHS phenotypes and mortality became stronger (Additional file 1, Table S1). Contrarily, when self-reports such as medication use and diabetes diagnosis were excluded from the assessment of MHS, the magnitude of the associations were weakened, and the negative association between MHOw and mortality in midlife became nonsignificant (Additional file 1, Table S2). If MH status was defined as the absence of any cardiometabolic abnormalities, MHO approximately doubled the risk for mortality in mid- and late-life compared to MHN (Additional file 1, Table S3). However, the low numbers of individuals with MHO may have contributed to the exceptionally high HRs for being MHO. Adding WC in the assessment of MHS did not affect the results qualitatively (Additional file 1, Tables S4 and S5).

Figure 3 compares the changes in estimates of BMI-MHS interactions for all-cause mortality from Model 8 (adjusted for primary covariates and CVD) with the model further adjusted for weight history. There were no statistically significant findings in the midlife sample. Neither a weight history of overweight nor obesity in midlife was associated with higher mortality. The elevated risk of mortality related to MUO in midlife became insignificant when further adjusted with weight history. In the late-life sample, a weight history of being overweight and obese was associated with an 11% and 32% increase in mortality risk. Further adjustment with weight history rendered the positive association of late-life MUOw and MUO with mortality risk insignificant. However, the higher HRs associated with late-life MUN and decreased HR associated with late-life MHOw remained robust to the adjustment.

Table 4 presents how the individual metabolic parameters used to define MHS relate to all-cause mortality. Out of the four metabolic parameters used to determine MHS, hyperglycemia had the largest effect size, increasing the mortality risk by 78% in the midlife group and 52% in the late-life group compared to normoglycemia. Hypertriglyceridemia in late-life was associated with a 9% increase in mortality, but the HR was not significant in midlife. Hypertension, BMI, and low HDL-C were not significantly associated with all-cause mortality, regardless of age at measurement. CVD in midlife was strongly associated with mortality risk, increasing the risk of mortality by nine times compared to those without a history of CVD, but with a time-varying effect such that HRs decreased by 3% per year of survival. In late-life, CVD was associated with a 33% increase in mortality risk.

Discussion
Summary of findings
To the best of our knowledge, this is the first study that examined both the independent and joint effects of BMI and MHS and their interactions on mortality in the same study population stratified into mid- and late-life. In this cohort of 6,252 individuals with measures taken in midlife, and 6,215 individuals with measures taken in late-life, being MU, is independently associated with an elevated risk of mortality, irrespective of BMI. Midlife and late-life overweight and obesity is associated with increased mortality risk only among those who were MU. Conversely, metabolically healthy overweight in late-life is associated with a reduced risk of mortality.

Independent effects of BMI and MHS in mid- and late-life
From the independent effect models, obesity, but not overweight, in both mid- and late-life was associated with increased mortality risk. The midlife results are consistent with other large cohort studies [4, 5], but the positive association between late-life obesity and mortality contrasts with many studies on older persons [2, 6–9]. Being MU in either age group was also associated with an elevated risk of mortality, aligning with meta-analyses on mortality risks associated with MetS in a population with a broad spectrum of ages [13] and older persons [34]. While the direction of the independent effects of high BMI and MU status on mortality was broadly similar in mid- and late-life, the magnitude of the effects from obesity and being MU in midlife were greater than in late-life. These findings highlight the importance of initiating prevention and
Fig. 3  Multivariable Cox Regression of all-cause mortality in relation to the interactions between body mass index and metabolic health status, not adjusted for weight history versus adjusted for weight history. Hazard ratios (HR) and 95% confidence intervals (CI) of all-cause mortality in relation to interactions between body mass index categories (BMI) and metabolic health status adjusted for weight history. We present Cox regression models adjusted for education, smoking, sex, and CVD, without and with weight history. Reference group is MHN – metabolically healthy normal weight. Bold numbers denote significance at the α = 0.05 level. Abbreviations: CVD—history of cardiovascular disease, MUN – metabolically unhealthy normal weight, MHOw – metabolically healthy overweight, MUOw – metabolically unhealthy overweight, MHO – metabolically healthy obesity and MUO – metabolically unhealthy obesity. Normal weight is defined as having BMI 18.5 – 24.9 kg/m²; overweight 25 – 29.9 kg/m²; obesity ≥ 30 kg/m². MU is defined as having ≥ 2 abnormal metabolic abnormalities.
interventions to manage obesity and metabolic dysfunction early in adulthood due to its potential long-term impact on survival.

Comparing the independent and joint effects of BMI and MHS
The effects of MHS on mortality remained relatively stable in the joint effect models, whereas the effects of obesity on mortality were attenuated compared to the independent effect models. Therefore, MHS is a stronger predictor of mortality than obesity in both mid- and late-life. In the interaction models, MU individuals had higher risks of mortality than the MH group, regardless of BMI category. Furthermore, individuals belonging to a lower BMI category who were MU carried higher mortality risks than those with a higher BMI and MH, consistent with past studies [35, 36]. A study conducted among older persons has also demonstrated that MetS accounted for 71.3% of a BMI and CVD association [37]. Collectively, these results suggest that MU status may be a primary driver of elevated mortality risk.

Effects of BMI and MHS interactions
Even among individuals with normal weight in late-life, being MU (MUN) increased the risk of mortality compared to MHN, consistent with past research [35, 36, 38, 39]. The raised mortality risk observed among those with MUN in late-life may result from reverse causality—weight loss from pre-existing illnesses. However, our findings show that the increased mortality risk in MUN was only slightly attenuated upon adjusting for weight history. This indicates that weight loss from overweight or obesity may not be key drivers to the excess mortality risk in MUN in late-life. Since the metabolic dysfunction in MUN is hidden in plain sight, detecting this phenotype is likely challenging. Greater attention to the evaluation of MHS may be necessary to better assess mortality risks, even in older adults with normal weight.

While individuals with higher BMI were likely to present with unfavourable metabolic profiles, we still found that within the group of people with obesity, 35.7% of the midlife sample and 36.1% of the late-life sample were metabolically healthy. The existence and prognosis of MHO is a subject that is debated in the literature. Our findings strengthen the evidence of past research demonstrating MHO as a nonsignificant risk of mortality [36, 39, 40]. Nonetheless, other studies have reported an increased [38, 41] or decreased [35, 42] risk of mortality among individuals with MHO. Some have attributed the heterogeneous findings to the various criteria and thresholds used in determining MHS and have called for consensus in the definitions [17, 43].

Criteria for defining MHS—findings from sensitivity analyses
It is important to note that only the magnitude of effects changed while the conclusions generally remained the same when various definitions of metabolic health were explored. One exception was the recently proposed criteria of MHS established systematically to distinguish MHO with decreased mortality by Zembic et al. [33]. Applying these new definitions did not substantially change our results in the midlife group (Additional file 1, Table S6). However, late-life MHO was significantly associated with a greater risk of mortality, corresponding with the findings in our sensitivity analysis, when metabolic health was defined with stricter criteria (absence of metabolic abnormality). It is noteworthy that the number of persons with MHO in our study

---

### Table 4 Multivariable Cox Regression of all-cause mortality in relation to individual metabolic abnormalities used to define metabolic health status

| Age          | Metabolic Abnormalities | HR  | 95% CI |
|--------------|-------------------------|-----|--------|
| \(<= 65 \text{ years} (n=6252)\) BMI categories | Normal weight Ref | 0.95 | 0.80—1.13 |
|              | Overweight 0.95 | 0.80—1.13 |
|              | Obesity 1.13 | 0.90—1.42 |
|              | Hypertension 1.00 | 0.85—1.19 |
|              | Hyperglycaemia 1.78 | 1.43—2.20 |
|              | Hypertriglyceridemia 1.13 | 0.94—1.36 |
|              | Low HDL-C 1.01 | 0.83—1.22 |
|              | CVD History 8.94 | 2.06—38.81 |
|              | CVD* 0.97 | 0.95—0.99 |
| \(> 65 \text{ years} (n=6215)\) BMI categories | Normal weight Ref | 0.93 | 0.87—1.00 |
|              | Overweight 0.93 | 0.87—1.00 |
|              | Obesity 1.10 | 0.99—1.21 |
|              | Hypertension 0.93 | 0.85—1.04 |
|              | Hyperglycaemia 1.52 | 1.38—1.67 |
|              | Hypertriglyceridemia 1.09 | 1.01—1.18 |
|              | Low HDL-C 1.02 | 0.94—1.11 |
|              | CVD History 1.33 | 1.25—1.43 |

Hazard ratios with 95% confidence intervals of all-cause mortality in relation to BMI category and individual metabolic abnormalities, adjusted for sex, education, and smoking

**Abbreviations:** HR hazard ratio, CI confidence interval, n sample size, Ref reference group, BMI body mass index, HDL-C high-density lipoprotein cholesterol levels, CVD cardiovascular disease, CVD* CVD as a time-varying covariate
dropped substantially when using the new definitions or stricter criteria, which may have explained the rise in mortality risks associated with MHO in late-life. Since these new criteria were derived systematically from a younger population with a mean age of 41.6 years, the risk pattern yielded from our midlife group was consistent with the study [33], as expected. Nonetheless, the findings from the late-life group were contradictory, thus raising concerns about whether criteria established in a midlife sample apply as well in late-life. Therefore, it may be justified to create age-specific criteria and cut-offs in the definitions of MHS and obesity.

Effects of MHOw in particular

The obesity paradox, the counterintuitive lower risks of mortality among those with high BMI, which tends to manifest in studies among older persons [2, 6–9], was not observed in our study. However, the lack of association between those with MHO and mortality and the negative association between MHOw in late-life and mortality highlight the role of MHS in generating paradoxical relations between high BMI and mortality. For example, an obesity paradox may present in a study population where individuals with higher BMI were metabolically healthier. Such a selection bias for healthier individuals tend to occur in many studies on aging.

This decline in mortality risk associated with MHOw in late-life casts doubts on weight loss recommendations for older persons who are metabolically healthy and overweight. Indeed, the latest nutrition and hydration guidelines in geriatrics established by the European Society for Clinical Nutrition and Metabolism advocated against weight-reducing diets for older individuals who are overweight [44]. The authors mentioned the accumulating evidence of the importance of metabolic risks; notwithstanding, there were no recommendations in assessing MHS as part of risk evaluation related to BMI.

The risk of mortality from individual metabolic components from sensitivity analysis

Among the metabolic components used to determine MHS, hyperglycaemia had the largest independent effects on mortality in both age categories, in line with previous literature [38, 45]. However, reports of how the rest of the metabolic components relate to mortality have been conflicting. While the association between hypertriglyceridemia in late-life and mortality in our study corresponds with the research findings derived from a younger study population [38], a meta-analysis found hypertriglyceridemia was protective among older persons with a median age of 73 years [45]. In our study, neither hypertension nor low HDL in mid- and late-life was associated with mortality, contradicting prior evidence [38, 45, 46]. The differences in how individual metabolic components relate to mortality may result from variations in age, pharmaceutical treatments, and the prevalence of metabolic dysfunctions in different study populations. Further investigations are necessary to understand this heterogeneity.

Although there is evidence that the effects of MHS are greater than BMI, the clinical importance of high BMI should not be downplayed. There is still substantial evidence linking high BMI to major non-communicable diseases, like CVD [47, 48], type II diabetes mellitus (T2DM) [48, 49] and cancer [50–52], which in turn predispose individuals to premature death. However, high BMI in itself may not be the proximal cause of mortality, thus explaining the weakened effects of BMI in the joint models and in interactions with MH status. Moreover, the dose-dependent increment in the prevalence of MU status among individuals from higher BMI categories in our study, in line with previous research [53], likely arises from the strong correlation between high BMI and metabolic dysfunction. Since metabolic parameters outside of the healthy range are well-recognized risk factors for CVD and T2DM [54], targeting both high BMI and impaired metabolic parameters is likely crucial in primary prevention.

Strengths and limitations

These findings contribute to understanding the gaps in our knowledge of how mid- and late-life BMI and MHS, independently, jointly, and in interactions, impact mortality. In addition, weight and height used in the derivation of BMI were measured objectively by trained, licensed nurses, thus reducing measurement errors. Moreover, we included weight history in our models to limit reverse causality. Furthermore, since the outcomes data were obtained from linked Tax registries in Sweden, we had comprehensive coverage of mortality.

There are some limitations to our study. Firstly, we included thresholds on non-fasting glucose and lipid levels, which may underestimate the prevalence of hyperglycemia and dyslipidemia. However, the proportion of non-fasting measures was relatively low. Secondly, using age as a timescale in the analysis limits the ability to account for period effects, such as differences in medication use over time on the population level. Thirdly, the mean follow-up time of the midlife group, at 13.9 years, meant our data in the midlife group is at risk of capturing mostly early deaths. Since the sensitivity analyses indicated that CVD in midlife was associated with a ninefold increase in the risk of death, premature death from CVD events likely accounted for most of the mortality...
in the midlife group. In addition, the unusually high HR of CVD may be an overestimation caused by the close link between CVD and MHS observed in other studies [55, 56]. Moreover, the estimates from the late-life group, with a mean follow-up time of 12 years, is potentially susceptible to reverse causation between lower BMI and mortality. Finally, to correct for potential bias due to weight loss from pre-existing morbidities, we adjusted the models for weight history, which did not drastically change the effects of BMI-MHS phenotypes.

Lastly, this study accounted for BMI and MHS only at baseline and could not capture the impact on mortality from the trajectories of BMI, MHS and the BMI-MHS phenotypes. When we included weight history in the models, the history of overweight and obesity heightened mortality risks, suggesting cumulative adverse effects from having high BMI. Furthermore, an extensive study of 90,257 women over 30 years supported the transient nature of BMI-MHS and showed that long periods of obesity increased CVD risk, despite preserved metabolic health [46]. The same study also concluded that many women with MHO transitioned to MUO over time. Future research should identify trajectories of BMI-MHS phenotypes and their impact on mortality.

Conclusions
In this large, prospective study of BMI and MHS in relation to mortality, we demonstrated that a metabolically unhealthy status, both in mid- and late-life, is an independent risk factor for mortality, robust to adjustment for CVD as well as BMI category. On the contrary, the association between high BMI and mortality changes in dependence upon MHS. Specifically, MHS influences the BMI-mortality association, such that overweight or obesity is not associated with excess risks of mortality in individuals with preserved metabolic health. In fact, being MHOw in late-life was associated with lower mortality risks. Therefore, sole assessment of BMI is likely insufficient and more nuanced evaluations of BMI together with MHS can more critically assess an individual’s mortality risk.

Abbreviations
BMI: Body mass index; BP: Blood pressure; CVD: History of cardiovascular disease; HDL-C: High-density lipoprotein cholesterol; HbA1c: Hemoglobin A1c; MetS: Metabolic Syndrome; MH: Metabolically healthy; MHS: Metabolic health status; MHN: Metabolically healthy normal weight; MHO: Metabolically healthy overweight; MHOw: Metabolically unhealthy overweight; MU: Metabolically unhealthy; MUN: Metabolically unhealthy normal weight; MUO: Metabolically unhealthy obesity; TG: Triglyceride levels.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-13082-3.

Additional file 1: Additional files. Table S1. Effects of body mass index and metabolic health status interaction on all-cause mortality when CVD was included as a component for ascertaining metabolic health. Table S2. Effects of body mass index and metabolic health status interaction on all-cause mortality, when self-reports were excluded from the ascertainment of metabolic health status. Table S3. Effects of body mass index and metabolic health status interaction on all-cause mortality, when metabolic health is defined as the absence of any metabolic abnormality. Table S4. Effects of body mass index and metabolic health status interaction on all-cause mortality, when waist circumference was included in the ascertainment of metabolic health status, and metabolic health is defined as ≤ two metabolic abnormalities. Table S5. Effects of body mass index and metabolic health status interaction on all-cause mortality when waist circumference is included in the ascertainment of metabolic health status, and metabolic health is defined as ≤ three metabolic abnormalities. Table S6. Effects of body mass index and metabolic health status interaction on all-cause mortality, when waist circumference was included as a component for ascertaining metabolic health. Table S7a. Effects of mid-life body mass index and metabolic health status interaction on all-cause mortality, stratified by sex. Table S7b. Effects of late-life body mass index and metabolic health status interaction on all-cause mortality, stratified by sex.

Acknowledgements
We would like to thank the Swedish Twin Registry for the access to data. We would also like to thank the participants of the Swedish Twin Registry.

Authors’ contributions
PL, IK, and ADA conceived the study concept. PL performed the data analyses and drafted the manuscript. XL contributed to the preparation of data. IK and ADA contributed to the statistical analysis plan, and supervised the statistical analyses. PL, XL, LH, CR, DF, IK and ADA contributed to the study design and the interpretation of the results. XL, LH, CR, DF, IK and ADA provided substantial contributions to the critical revision of the manuscript for important intellectual content. All authors approved the final manuscript for submission.

Funding
Open access funding provided by Jönköping University. This work was supported by the Swedish Research Council (2016–03081), the Swedish Research Council for Health, Working Life and Welfare (2018–01201), the National Institutes of Health (NIH AG060470), and the Strategic Research Program in Epidemiology (SfoEpi) at the Karolinska Institutet. We acknowledge the Swedish Twin Registry, managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no. 2017–00,641. The sub-studies of the Swedish Twin Registry were supported by the National Institutes of Health (grants R01 AG10175, R01 AG08724, R01 AG08861, R01 AG028555, and U01 DK066134), the MacArthur Foundation Research Network on Successful Aging, the Axel and Margaret Axelson Johnsons Foundation, the Swedish Research Council, the Swedish Foundation for Health Care Sciences and Allergy Research, and the Swedish Council for Working Life and Social Research (2013–2292). The funding bodies played no role in the design of the study, collection, analysis, and interpretation of the data, and in the writing of the manuscript.

Availability of data and materials
The data that support the findings of this study are from the Swedish Twin Registry. Data can be applied for at https://ki.se/en/research/swedish-twin-registry-for-researchers.
Declarations

Ethics approval and consent to participate
The study was approved by the Regional Ethical Review Board Stockholm in Sweden (2015/1729 – 35/5). Written informed consent were obtained from all participants of the Swedish Twin Registry.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Aking Research Network-Jönköping (ARN-J), School of Health and Welfare, Jönköping University, Jönköping, Sweden. 2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3 Department of Psychology and Centre for Ageing and Health, University of Gothenburg, Gothenburg, Sweden. 4 Department of Psychology, University of California - Riverside, Riverside, CA, USA. 5 Department of Psychology, Indiana University Southeast, New Albany, Indiana, USA. 6 School of Health Sciences, University of Skövde, Skövde, Sweden.

Received: 11 October 2021   Accepted: 25 March 2022

Published online: 11 April 2022

References

1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Esteve K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13–27.
2. Sun YQ, Burgess S, Staley JR, Wood AM, Bell S, Kaptoge S, et al. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ. 2019;364:l4042.
3. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.7 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.
4. Global BMIMC, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, et al. Body-mass index and all-cause mortality: a meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–86.
5. Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas LS, Smeeth L. Association of BMI with all cause and specific cause mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–53.
6. Yi SW, Ohr H, Shin YA, Yi JJ. Sex-age-specific association of body mass index with all-cause mortality among 12.8 million Korean adults: a prospective cohort study. J Epidemiol. 2013;23(5):1696–705.
7. Dahl AK, Fauth EB, Ensmth-Bravell M, Hassing LB, Ram N, Gerdot S. Body mass index, change in body mass index, and survival in old and very old persons. J Am Geriatr Soc. 2013;61(4):1212–8.
8. Janssens I, Mark AE. Elevated body mass index and mortality risk in the elderly. Obes Rev. 2007;8(1):41–59.
9. Veronese N, Cereda E, Solmi F, Fowler SA, Manzato E, Maggi S, et al. Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. Obes Rev. 2015;16(11):1001–15.
10. Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nawson CA. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875–90.
11. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.
12. Ransinghde P, Mathangasinghe Y, Jayawarden a R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(1):101.
13. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25(6):375–84.
14. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(4):1113–32.
15. Hildrum B, Myklesten A, Dahl AA, Midtghjell K. Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trondelag Health Study (HUNT). Diabetologia. 2009;52(4):583–90.
16. Kane AE, Gregson E, Theou O, Rockwood K, Howlett SE. The association between frailty, the metabolic syndrome, and mortality over the lifespan. Geroscience. 2017;39(2):221–9.
17. Bluhmer M. Metabolically Healthy Obesity. Endocr Rev. 2020;41(3):bmaa004.
18. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16.
19. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617–24.
20. Karelis AD, St-Pierre DH, Conus F, Babasa-Hloret R, Pohelman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89(6):2569–75.
21. van Vliet-Ostaptchouk JV, Nuortio ML, Slagter SN, Doorn E, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.
22. Yeh TL, Chen HH, Tsai SY, Lin CY, Liu SJ, Chien KL. The relationship between Metabolically Healthy Obesity and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Clin Med. 2019;8(8):1228.
23. Roberson LL, Arrieta EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health. 2014.;14:14.
24. Orio J, Croker E, Ondog AS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: A systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21(12):13127.
25. Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health. 2016;70(10):1024–3.
26. Zagar LJ, Lichtenstein P, Pedersen NL, Magnusson PKE. The Swedish Twin Registry: Content and Management as a Research Infrastructure. Twin Res Hum Genet. 2019;22(6):672–80.
27. Gold CH, Malmberg B, McClean GE, Pedersen NL, Berg S. Gender and Health: A Study of Older Unlike-Sex Twins. J Gerontol Series B. 2002;57(3):5168–76.
28. McClean GE, Johansson B, Berg S, Pedersen NL, Ahern E, Petrelli SA, et al. Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science. 1997;276(5318):1560–3.
29. Pedersen NL, McClean GE, Plomin R, Nesselroade JR, Berg S, DeFaire U. The Swedish Adoption Twin Study of Aging: an update. Acta Genet MedGemellol (Roma). 1991;40(1):7–20.
30. Magnusson PK, Almqvist C, Rahman I, Ganna A, Viktorin A, Walum H, et al. The prevalence of metabolic syndrome and metabolically healthy obesity: a meta-analysis of 239 prospective studies in four continents. BMJ 2015;353:h4042.
31. World Health Organization Consultation on Obesity (1999). Geneva, Switzerland & World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Geneva. 2000.
32. Alberti KG, Eckel RH, Grundy SM, Zimet PD, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association; World Health Federation; International Atherosclerosis...
Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.
33. Zembic A, Eckel N, Stefan N, Baudry J, Schulze MB. An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality. JAMA Netw Open. 2021;4(5):e218505.
34. Kim YH, Kim SM, Han KD, Son JW, Lee SS, Oh SW, et al. Change in Weight and Body Mass Index Associated With All-Cause Mortality in Korea: A Nationwide Longitudinal Study. J Clin Endocrinol Metab. 2017;102(11):4041–50.
35. Cheng FW, Gao X, Mitchell DC, Wood C, Rolston DD, Still CD, et al. Metabolic Health Status and the Obesity Paradox in Older Adults. J Nutr Gerontol Geriatr. 2016;35(3):161–76.
36. Al-Khalidi B, Kuk JL, Ardern CI. Lifetime risk of cardiometabolic mortality according to vitamin D status of middle and older-aged adults. NHANES III mortality follow-up. J Steroid Biochem Mol Biol. 2019;186:34–41.
37. Dhana K, Koolhaas CM, van Rossum EF, Ikram MA, Hofman A, Kavousi M, et al. Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the Elderly Population. PLOS One. 2016;11(4):e0154273.
38. Hinnouho GM, Czernichow S, Dugravot A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care. 2013;36(8):2294–300.
39. Kuk JL, Rotondi M, Sui X, Blair SN, Ardern CI. Individuals with obesity but no other metabolic risk factors are not at significantly elevated all-cause mortality risk in men and women. Clin Obes. 2018;8(5):305–12.
40. Durward CM, Hartman TJ, Nickols-Richardson SM. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. J. Obes. 2012;2012:60321.
41. Loprinzi PD, Frith E. Cardio-metabolic healthy obesity paradigm and all-cause mortality risk. Eur J Intern Med. 2017;43:42–5.
42. Huang MY, Wang MY, Lin YS, Lin CJ, Lo K, Chang LJ, et al. The Association between Metabolically Healthy Obesity, Cardiovascular Disease, and All-Cause Mortality Risk in Asia. A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020;17(4):1320.
43. Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62(4):558–66.
44. Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Geisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019;38(1):10–47.
45. Ju SY, Lee JY, Kim DH. Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96(45):e8491.
46. Eckel N, Li Y, Kuchhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714–24.
47. Emerging Risk Factors C, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95.
48. Riaz H, Khan MS, Siddiqi TJ, Usman MS, Shah N, Goyal A, et al. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. JAMA Netw Open. 2018;1(7):e183788.
49. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309–19.
50. Goh DP, Zhang W, Bansback N, Amari Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;88.
51. Han X, Stevens J, Truesdale KP, Bradshaw PT, Kucharska-Newton A, Pritzmen AE, et al. Body mass index at early adulthood, subsequent weight change and cancer incidence and mortality. Int J Cancer. 2014;135(12):2900–9.
52. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer-Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
53. Magkos F. Metabolically healthy obesity: what’s in a name? Am J Clin Nutr. 2019;10(3):533–9.
54. Bays HE. Adiposopathy is “sick fat” a cardiovascular disease? J Am Coll Cardiol. 2011;57(25):2461–73.
55. Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, Toledo E, Moreno-Iribas C, Investigators RS. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19(1):195.
56. Watanabe J, Kotani K. Metabolic Syndrome for Cardiovascular Disease Morbidity and Mortality Among General Japanese People: A Mini Review. Vasc Health Risk Manag. 2020;16:149–55.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.